



STATE OF THE ART DRUG DEVELOPMENT
IN EARLY ALZHEIMER'S DISEASE

Please Join for a Virtual R&D Event with Key Opinion Leaders

Tuesday, October 17, 2023
at 1:30PM CEST (7:30AM EDT)

Featuring presentations and a moderated panel discussion on the design and rationale of the VIVIAD Phase 2b study of varoglutamstat in Alzheimer's disease followed by Q&A.

Featured Speakers:



Moderator - Philip Scheltens, M.D., Ph.D.

Professor Emeritus, Amsterdam University Medical Centers; Founder and Past Director of the Alzheimer Center at Amsterdam University Medical Centers; Partner and Head of the Dementia Fund, EQT Life Sciences



Stephan Schilling, Ph.D.

Professor for Drug Biochemistry, Anhalt University of Applied Sciences; Head of the Department for Drug Design and Target Validation, Fraunhofer Institute for Cell Therapy and Immunology (IZI)



John Harrison, Ph.D.

Chief Scientific Officer, Scottish Brain Sciences; Associate Professor, Alzheimer Center at Amsterdam University Medical Centers



Sietske Sikkes, Ph.D.

Associate Professor, Department of Clinical, Neuro and Developmental Psychology of the VU University, and Alzheimer Center at Amsterdam University Medical Centers



Willem de Haan, Ph.D.

Neurologist and Senior Researcher, Alzheimer Center at Amsterdam University Medical Centers



Frank Weber, M.D.

Chief Executive Officer and Chief Medical Officer, Vivoryon Therapeutics

RSVP – [Click here to register](#), registration is required.

You are welcome to submit questions in advance to
israel.danesh@sternir.com